CA19-9在膽囊癌診斷中的價值_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

石景森 , 秦興雷

Corresponding?author：

Keywords：

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 石景森,秦興雷. CA19-9在膽囊癌診斷中的價值. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 1997, 4(2): 110-111. doi: Copy

1.	Scott JR,Carcinoma of the gallbladder.Surg Clin N Am,1990;70(6):1419.
2.	Dearetxabalax.早期膽囊癌的手術所見.國外醫學外科學分冊,1990;17(4):236.
3.	石景森.膽囊癌的外科診治.肝膽胰脾外科雜志,1996;2(3):132.
4.	Koporwski H,Steplewski Z,Mitchei K.Colon-rectal carcionma antigendetected by hybridoma antibodies.Somatic Cell Genetics,1979;5:957.
5.	Koporwski H,Steplewski Z,Mitchei K.Specific antigen in serum of patients with colon carcinoma.Science,1981;212:53.
6.	Del Villano BC.Radioimmunological assay for monoclonal antibydy-defined tumormarker CA19-9.Clin Chem,1983;29:549.
7.	Ohshic G,Monahe T,Watamobe Y,et al.Comparative studies of DU-PAN-2,CEA,and CA19-9 in the serum and bile of patients with pancreatic and billiary tract disease:evaluations of the influence of obstructive jaundice.Am J Gastroenterol.1990;85(10):1370.
8.	Albert MB,Steinberg WM.Elevated serum levels of tumor marker CA19-9 in acute cholangitis.Dig Dis Sci,1988;33:1223.
9.	Hoglund C,Roberts PJ,Kuusela P,et al.Evaluation of CA19-9 as an serum tumor marker in pancreatic cancer.Br J Cancer,1986;53(2):197.
10.	陸雪龍,王百正,時紅珍.CA19-9RIA的臨床觀察，放射免疫學雜志,1992;5(4):222.
11.	Berotta.Serum CA19-9 in the post surgical follow-up of patients with pancreatic cancer.Cancer,1987;60:2426.
12.	Ker CG,Chen JS,Lee KT,et al.Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma.J Gastroenterol Hepatol,1991;6(5):505.
13.	許昌泰,潘伯榮.腫瘤標記CA19-9的臨床研究.日本醫學介紹,1990；11(2):93.

1. Scott JR,Carcinoma of the gallbladder.Surg Clin N Am,1990;70(6):1419.
2. Dearetxabalax.早期膽囊癌的手術所見.國外醫學外科學分冊,1990;17(4):236.
3. 石景森.膽囊癌的外科診治.肝膽胰脾外科雜志,1996;2(3):132.
4. Koporwski H,Steplewski Z,Mitchei K.Colon-rectal carcionma antigendetected by hybridoma antibodies.Somatic Cell Genetics,1979;5:957.
5. Koporwski H,Steplewski Z,Mitchei K.Specific antigen in serum of patients with colon carcinoma.Science,1981;212:53.
6. Del Villano BC.Radioimmunological assay for monoclonal antibydy-defined tumormarker CA19-9.Clin Chem,1983;29:549.
7. Ohshic G,Monahe T,Watamobe Y,et al.Comparative studies of DU-PAN-2,CEA,and CA19-9 in the serum and bile of patients with pancreatic and billiary tract disease:evaluations of the influence of obstructive jaundice.Am J Gastroenterol.1990;85(10):1370.
8. Albert MB,Steinberg WM.Elevated serum levels of tumor marker CA19-9 in acute cholangitis.Dig Dis Sci,1988;33:1223.
9. Hoglund C,Roberts PJ,Kuusela P,et al.Evaluation of CA19-9 as an serum tumor marker in pancreatic cancer.Br J Cancer,1986;53(2):197.
10. 陸雪龍,王百正,時紅珍.CA19-9RIA的臨床觀察，放射免疫學雜志,1992;5(4):222.
11. Berotta.Serum CA19-9 in the post surgical follow-up of patients with pancreatic cancer.Cancer,1987;60:2426.
12. Ker CG,Chen JS,Lee KT,et al.Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma.J Gastroenterol Hepatol,1991;6(5):505.
13. 許昌泰,潘伯榮.腫瘤標記CA19-9的臨床研究.日本醫學介紹,1990；11(2):93.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

CA19-9在膽囊癌診斷中的價值

Abstract Full text Figures/Tables Video References Cited by

Format

Content